Response to: 'Comparing the immunogenicity of the etanercept biosimilar SB4 with the innovator etanercept: another consideration' by Marshall et al.
作者信息
Emery Paul, Vencovský Jiří, Ghil Jeehoon, Kang Jung Won
机构信息
Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
Institute of Rheumatology, Prague, Czech Republic.
出版信息
Ann Rheum Dis. 2016 Jul;75(7):e38. doi: 10.1136/annrheumdis-2016-209517. Epub 2016 May 4.
Abstract
摘要
相似文献
1
Response to: 'Comparing the immunogenicity of the etanercept biosimilar SB4 with the innovator etanercept: another consideration' by Marshall et al.对马歇尔等人所著《比较依那西普生物类似药SB4与原研依那西普的免疫原性：另一个考量因素》的回应
Ann Rheum Dis. 2016 Jul;75(7):e38. doi: 10.1136/annrheumdis-2016-209517. Epub 2016 May 4.
2
Comparing the immunogenicity of the etanercept biosimilar SB4 with the innovator etanercept: another consideration.比较依那西普生物类似药SB4与原研依那西普的免疫原性：另一项考量
Ann Rheum Dis. 2016 Jul;75(7):e37. doi: 10.1136/annrheumdis-2016-209502. Epub 2016 Mar 31.
3
Post-switch Effectiveness of Etanercept Biosimilar Versus Continued Etanercept in Rheumatoid Arthritis Patients with Stable Disease: A Prospective Multinational Observational Study.依那西普生物类似药转换治疗与继续使用依那西普治疗对病情稳定的类风湿关节炎患者的疗效：一项前瞻性多国观察性研究。
Adv Ther. 2022 Nov;39(11):5259-5273. doi: 10.1007/s12325-022-02303-1. Epub 2022 Sep 22.
4
52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis.在活动性类风湿关节炎患者中比较SB4与参比药物依那西普的3期随机研究的52周结果。
Rheumatology (Oxford). 2017 Dec 1;56(12):2093-2101. doi: 10.1093/rheumatology/kex269.
5
Long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: an open-label extension of a phase III multicentre, randomised, double-blind, parallel-group study.在继续接受依那西普生物类似药（LBEC0101）或从参照依那西普转换为 LBEC0101 的类风湿关节炎患者中的长期疗效、安全性和免疫原性：一项 III 期、多中心、随机、双盲、平行组研究的开放性扩展。
Arthritis Res Ther. 2019 May 21;21(1):122. doi: 10.1186/s13075-019-1910-2.
6
A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy.一项III期随机、双盲、平行组研究，在尽管接受甲氨蝶呤治疗但仍患有活动性类风湿关节炎的患者中，将SB4与依那西普参比产品进行比较。
Ann Rheum Dis. 2017 Jan;76(1):51-57. doi: 10.1136/annrheumdis-2015-207588. Epub 2015 Jul 6.
7
Etanercept for the treatment of rheumatoid arthritis.依那西普用于治疗类风湿关节炎。
Immunotherapy. 2018 Mar 1;10(6):433-445. doi: 10.2217/imt-2017-0155. Epub 2018 Feb 27.
8
Comparison of injection-site reactions between the etanercept biosimilar SB4 and the reference etanercept in patients with rheumatoid arthritis from a phase III study.一项III期研究中类风湿关节炎患者使用依那西普生物类似药SB4与参比依那西普的注射部位反应比较。
Br J Dermatol. 2018 Mar;178(3):e215-e216. doi: 10.1111/bjd.16032. Epub 2018 Jan 30.
9
Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis.类风湿关节炎依那西普生物类似药试验和数据回顾。
Curr Rheumatol Rep. 2018 Nov 9;20(12):84. doi: 10.1007/s11926-018-0799-0.
10
LBEC0101, an etanercept biosimilar for the treatment of rheumatoid arthritis.LBEC0101，一种用于治疗类风湿性关节炎的依那西普生物类似药。
Expert Opin Biol Ther. 2021 Jan;21(1):1-8. doi: 10.1080/14712598.2020.1701650. Epub 2019 Dec 20.
引用本文的文献
1
52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis.在活动性类风湿关节炎患者中比较SB4与参比药物依那西普的3期随机研究的52周结果。
Rheumatology (Oxford). 2017 Dec 1;56(12):2093-2101. doi: 10.1093/rheumatology/kex269.
Zotero 插件